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ABSTRACT 
Acute cerebral hypoxia causes rapid calcium shifts leading to neuronal damage and death. 
Calcium channel antagonists improve outcomes in some clinical conditions, but 
mechanisms remain unclear. 
 
In 18 healthy participants we: (i) quantified with multiparametric MRI the effect of hypoxia 
on the thalamus, a region particularly sensitive to hypoxia, and on the whole brain in 
general; (ii) investigated how calcium channel antagonism with the drug nimodipine affects 
the brain response to hypoxia. 
 
Hypoxia resulted in a significant decrease in apparent diffusion coefficient (ADC), a 
measure particularly sensitive to cell swelling, in a widespread network of regions across 
the brain, and the thalamus in particular. In hypoxia, nimodipine significantly increased 
ADC in the same brain regions, normalizing ADC towards normoxia baseline. There was 
positive correlation between blood nimodipine levels and ADC change. In the thalamus, 
there was a significant decrease in the amplitude of resting-state functional MRI (ALFF) 
and an apparent increase of grey matter volume in hypoxia, with the ALFF partially 
normalized towards normoxia baseline with nimodipine. 
 
This study provides further evidence that the brain response to acute hypoxia is mediated 
by calcium, and importantly that manipulation of intracellular calcium flux following hypoxia 
may reduce cerebral cytotoxic oedema 
 
Key Words 
 
ADC, Calcium, Hypoxia, MRI, Nimodipine  
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INTRODUCTION 
Many important cellular processes are mediated by calcium. The movement and storage 
of calcium in cells are subject to tight regulatory control, primarily through the action of 
voltage gated calcium channels (L-type channels).1 In neurons, these calcium channels 
are the principal source for calcium entry and membrane depolarization after energy 
failure.2,3 Drugs, such as nimodipine, that block these calcium channels may reduce 
calcium influx into neurons and play a key role in limiting neuronal cellular damage due to 
oxygen deprivation (cerebral hypoxia).2 
 
Nimodipine is an L-type calcium channel blocker characterized by a highly selective action 
on cerebral blood vessels and a high affinity for receptors in the brain.4,5 This preferential 
cerebral action of the drug has been explained by high transfer across the blood-brain 
barrier compared with other calcium channel blockers.6 Nimodipine has been shown to 
improve outcomes after brain haemorrhage, but this effect does not extend to other types 
of acute brain injury such as trauma and stroke where there is restriction in blood supply 
(ischaemia).7 The precise mechanisms behind this beneficial effect remain unclear, but is 
likely to be related to blocking calcium influx after tissue ischaemia at a neuronal level.8  
 
In both focal and global cerebral ischaemia, there is substantial evidence of variability in 
the tolerance of different brain regions to hypoxic-ischaemic damage. Sub-cortical 
structures including the thalamus, the hypothalamus, basal ganglia and cerebellum are 
particularly sensitive to hypoxic-ischaemic injury,9-11 with the thalamus in particular 
showing early vulnerability in the acute phase.12 Poor functional recovery, (specifically in 
memory) has also been linked to damage in the thalamus in animal studies,13 as well as 
cognitive dysfunction in patients surviving cardiac arrest and traumatic brain injury.14,15 The 
thalamus is therefore a particularly interesting brain structure in which to investigate the 
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role of calcium in mediating cerebral injury following hypoxia, especially as thalamic 
voltage dependent calcium channels are likely to play a key role in higher-level cortical 
functions.16 
 
Exposure of healthy volunteers to experimental hypoxia potentially offers a model of in 
vivo reversible brain injury. Heterogeneous changes in diffusion weighted imaging metrics 
(e.g. apparent diffusion coefficient (ADC) – an MRI marker of cerebral oedema), cerebral 
blood flow (CBF) and cerebral volume have all been previously reported after acute 
hypoxia.17-19 There has also been recent interest in the significance of the amplitude of low 
frequency oscillations (ALFF) (0.01 to 0.1Hz) of resting state functional MRI in health and 
in disease. Changes in ALFF have been observed following traumatic brain injury20 and in 
Parkinson’s disease.21 Low frequency oscillations in calcium (known as a biomarker of 
cellular oscillations) show frequencies similar to those of deoxyhemoglobin (the main 
contributor to the BOLD MRI signal) and precede them by 5–6s.22 Changes in ALFF due to 
cellular calcium flux might therefore represent a biomarker of acute cerebral tissue hypoxia 
and be influenced by calcium channel blockade with nimodipine. 
 
The purpose of this study was two-fold: first, to test the hypothesis that acute hypoxia 
would have a significant effect on the thalamus, and second, that this hypoxic effect would 
be attenuated by the administration of nimodipine. To test these hypotheses, the 
objectives of this study was to quantify changes in ADC, grey matter volume, cerebral 
blood flow and ALFF associated with acute hypoxia using MRI in healthy humans. We 
then aimed to investigate the impact of calcium channel blockade with nimodipine on 
these changes, to offer mechanistic insights into therapeutic calcium channel blockade 
clinically in patients.  
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MATERIALS AND METHODS 
The study was conducted in accordance with the Helsinki Declaration as revised in 2008 
and was approved by the local UK National Research Ethics Service Committee (NRES 
Committee South Central – Berkshire: 11/SC/0519). Informed written consent was 
obtained from all participants. 20 right handed, healthy volunteers (11 males and 9 
females, mean age 28 ± 8 years) with no regular medication were recruited. Specific 
exclusion criteria included routine contraindications to MRI scanning, history of smoking 
and recent air travel or exposure to high altitude within the last month. 
 
Experimental Design 
Participants attended four separate experimental sessions (a minimum of one week apart). 
Each session lasted approximately five hours in total. The experiment was a factorial 
design with the order of each session randomised for each subject. The experimental 
conditions are shown in Figure 1A and were as follows:  
 
1. Poikilocapnic normoxia (“normoxia”)/Placebo 
2. Poikilocapnic normoxia (“normoxia”)/Nimodipine 
3. Poikilocapnic hypoxia (“hypoxia”)/Placebo 
4. Poikilocapnic hypoxia (“hypoxia”)/Nimodipine 
 
All conditions were normobaric. Drug/placebo conditions were double blinded for each 
session with doses prepared by an individual independent of the research group. 
Participants were blinded to gas mixture in all sessions. The researchers running each 
experimental session were not blinded to the gas mixture. First level MRI analysis was 
undertaken blinded to both normoxia/hypoxia and drug/placebo conditions. Un-blinding 
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was only performed once all first level MRI pre-processing and analysis had been 
completed. 
 
Experimental Procedure  
The study protocol consisted of a continuous four hour session in a physiology laboratory 
breathing either room air, with the usual fraction of inspired oxygen (FiO2) of 21%, or a 
hypoxic gas mixture with the partial pressure of end-tidal oxygen (PETO2) maintained at 
7.3KPa, followed by an MRI scan with PETO2 maintained at the same level as during the 
preceding four hours. Depending on the session protocol (as per Figure 1A), participants 
received either nimodipine 30mg or placebo at both one hour and three hours into the 
protocol depending on the experimental condition. 
 
Acute hypoxia 
Modulation of inspired O2 content during both the laboratory and MRI sessions was 
achieved using a custom-built breathing apparatus (Figure 1B). During the laboratory 
hypoxia condition, subjects inhaled gas from a hypoxicator unit (HYP-123 Hypoxicator 
generator, Hypoxico Inc) with an FiO2 of 12% (equivalent to an altitude of 4400m) via a 
tight-fitting silicone facemask (Hans Rudolph, 7540 series V2, Kansas City, MO, USA) to 
maintain an PETO2 of 7.3KPa. Additional 7% O2 in nitrogen from a cylinder was added as 
required to ensure tight control of PETO2 for each participant. During the normoxia 
condition, subjects received medical air at the same rate through the same system.  
 
The partial pressure of end-tidal carbon dioxide (PETCO2) was not experimentally 
controlled during the laboratory and MRI sessions to replicate normal cerebral 
physiological responses to hypoxia. Continuous physiologic recordings were obtained for 
PETCO2 and PETO2 (Gas Analyzer, AD Instruments, UK). Oxygen saturations (SpO2), 
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heart rate and non-invasive blood pressure (NIBP) were measured every five minutes 
(Dinamap Procare 300, GE Healthcare). For each subject, the hypoxicator was turned on 
during all four sessions to ensure the background noise was the same and that subjects 
remained blinded to the gas mixture condition. During the MRI session, participants used a 
similar breathing apparatus and a diving mouth-piece (Scubapro Ltd, UK) to maintain the 
same PETO2 as used in the laboratory session for the duration of the MRI scan. 
 
Study drug  
Nimodipine and placebo doses were produced by Ipswich NHS Pharmacy Manufacturing 
Unit. Capsules were matched in colour, size and shape to ensure both participants and 
investigators remained blinded to the experimental condition. The dosing and oral route 
were chosen to replicate standard clinical practice in patients with subarachnoid 
haemorrhage and timed to aim for maximum serum concentrations of the drug at the start 
of the MRI scanning session (based on data from Hernández-Hernández R. et al23). 
Although it was difficult to ensure peak concentrations of nimodipine at the same timepoint 
in each session, blood samples were taken from each participant at the 4 hours mark in 
each session and any delay between blood sampling and MRI scanning was the same for 
each session. Serum nimodipine levels were then measured using customised mass 
spectroscopy (Sequani Ltd). 
 
MRI Scanning  
A Siemens MAGNETOM 3T Verio scanner (Siemens Healthcare, Erlangen, Germany) 
situated immediately adjacent to the physiology laboratory was used for all scanning 
sessions. At the end of the four-hour laboratory session, participants were moved 
immediately to the scanner room and placed directly onto the breathing system. 
Disconnection time was kept to an absolute minimum. Heart rate, oxygen saturations 
	 8	
(SpO2) and non-invasive blood pressure (NIBP) were continuously monitored during MRI 
scans using an MRI-compatible physiological monitoring system (3150/3155 MRI patient 
monitor, In Vivo Research). Tidal O2 and CO2 were monitored using a gas analyzer (Gas 
Analyzer, AD Instruments, NZ). 
 
The scanning protocol included: 
 
• T1-weighted MPRAGE structural, to measure changes in grey matter (GM) 
volume: 2 mins 22 s, whole brain; 1.5 x 1.5 x 1.5mm resolution; TR 1780 ms; TI 
900 ms; TE 4.4 ms 
• Diffusion-weighted (DWI) echo planar, spin echo sequence, to measure 
changes in ADC: 1 min; TR 5300 ms; TE 91 ms; b values 0 and 1000 s/mm2, voxel 
size 1.8 x 1.8 x 5mm; 25 slices, isotropic encoding 
• Time-of-flight MR neck angiogram, to facilitate vessel labeling:1.5 mins; 20 
slices; 1.2 x 0.8 x .1.3 mm; TR 26 ms; TE 3.43 ms; flip angle 18 degrees 
• Multi-inversion time (TI), vessel-encoded pseudo-continuous arterial spin 
labeling (VEPCASL) perfusion-weighted imaging, to measure changes in CBF 
(as per Okell et al., 201324): 5 mins 55 s, 3.4 x 3.4 x 4.5 mm, field of view 220mm; 
TR 4080 ms; TE 14 ms, echo planar imaging readout, 24 slices, background 
suppression with multiple post-labeling delays (tag duration 1.4 s with six delays: 
0.25 s, 0.5 s, 0.75 s, 1 s, 1.25 s, 1.5 s) along with calibration scans acquired with 
both head and body coils for signal reception (24 s each, TR 6000 ms) 
• Phase contrast scan, to quantify flow velocities through carotid/vertebral 
vessels: 1 min 27 s, 1.9 x 1.9 x 5mm, TR 58.75 ms, TE 6.06 ms, flip angle 15 
degrees, VENC 100cm/s 
	 9	
• Resting state gradient-echo, echo-planar blood oxygen dependent level 
(BOLD) imaging sequence - to measure low frequency fluctuations in the 
BOLD signal: 6 mins; TR 3000 ms; TE 40 ms; flip angle 90°; FOV 240 mm; voxel 
size 3.0 x 3.0 x 3.0 mm, 40 slices 
• B0 fieldmap images – to aid registration by correcting for echo-planar imaging 
distortion artifacts 
 
The scanning protocol was ordered as presented above and was conducted in the same 
order for each experimental session. To quantify any potential change in velocity through 
the carotid and vertebral arteries due to either hypoxia or nimodipine, phase contrast 
images were acquired. This technique utilizes the phase of an image to encode the 
velocity of flowing spins and has been validated for angiogram and quantitative flow 
measurements.25 
 
Post-processing of MRI data  
All imaging analyses were carried out using FSL Version 5.0 (FMRIB Software Library, 
Functional Magnetic Resonance Imaging of the Brain Centre, Department of Clinical 
Neurosciences, University of Oxford, Oxford, UK, http://www.fmrib.ox.ac.uk26) unless 
otherwise specified. 
Volumetric structural data analysis 
An optimized voxel-based morphometry (VBM) analysis was undertaken on the T1-
weighted images to identify regional changes in the thalamus and whole brain grey matter 
volume (FSL-VBM: http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLVBM27). All images were 
processed following the same protocol: first, structural images from all four experimental 
conditions, in all subjects, were brain-extracted and grey matter-segmented before being 
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registered to the MNI152 standard space using non-linear registration. The resulting 
images were averaged and flipped along the x-axis to create a left-right symmetric, study-
specific grey matter template. Second, all native grey matter images were non-linearly 
registered to this study-specific template and "modulated" to correct for local expansion (or 
contraction) due to the non-linear component of the spatial transformation. The modulated 
grey matter images were then smoothed with an isotropic Gaussian kernel with a sigma of 
3mm. A thresholded (at 35%) binarised probabilistic mask (Harvard-Oxford, FSL) of the 
thalamus in MNI152 standard space was used to obtain values for grey matter volume of 
both the thalami.   
 
We also investigated voxel-wise changes in volume over the whole brain grey matter, 
using permutation-based non-parametric testing (5,000 permutations), correcting for 
multiple comparisons across space (see Statistical analysis section below for further 
details). 
 
DWI data analysis  
ADC maps obtained from the scanner were brain extracted using the FSL tool BET28 and 
registration of the B0 image to the native T1-weighted image was estimated for each 
subject with boundary based recognition.29-31 Next, we combined this within-subject 
registration with the non-linear registration of each subject’s grey matter-segmented image 
to the VBM template. At the end of this registration process, ADC maps were therefore in 
the study-specific VBM template space to ensure optimal group registration. The same 
probabilistic mask of the thalamus used in the VBM analysis was applied to maps from 
each condition to obtain average values for each participant. Finally, voxel-wise statistical 
test was applied using permutation-based non-parametric testing to look for changes in 
grey matter ADC across the whole brain between the conditions of interest. 
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Perfusion-weighted data analysis 
All related data processing steps essential for quantification of CBF including tissue 
segmentation, estimation of equilibrium magnetization of blood (M0b) from the mean CSF 
(cerebrospinal fluid) magnetization (M0csf) within a ventricle mask, and generation of 
absolute CBF in physiologic units (ml blood/100g tissue/minute) were completed using 
FSL tools and MATLAB (MATLAB R2015a, The MathWorks Inc., Natick, MA, 2000) as per 
Okell et al., 2013.24 
 
Firstly, head motion was corrected using multi-resolution rigid body co-registration of 
volumes, as implemented by MCFLIRT. Then multi-TI VEPCASL data was processed 
using a non-linear fit to the general arterial spin labeling (ASL) kinetic model for all voxels 
within a whole brain mask, accounting for macrovascular signal, to quantify CBF.24,32 
Similarly to the ADC analysis, total perfusion maps were registered to the study-specific 
VBM template space by combining the spatial transformation of each calibration body EPI 
image to the same subject’s T1-weighted image with the corresponding VBM warpfield. 
Again, the probabilistic mask of the thalamus was used to obtain average values for 
thalamic CBF. 
 
Phase contrast MRI was used to assess the blood velocity in the carotid and vertebral 
arteries at the location of the PCASL labelling plane.25 The phase contrast MRI acquisition 
was cardiac-gated using a pulse oximeter. Vessel ROIs were manually created and 
applied to the cardiac gated velocity maps to provide plots of blood velocity over the 
cardiac cycle. Average velocity was then computed and compared to a simulated plot of 
inversion efficiency versus velocity. Average vessel velocities in the range of 15 cm/s to 45 
cm/s result in an inversion efficiency of approximately 0.933, and were in this range for all 
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subjects. As a result, the effects of blood velocity at the labelling plane on inversion 
efficiency were likely to be consistent across all subjects. 
 
Amplitude of low frequency fluctuations analysis: 
Head motion was corrected using multi-resolution rigid body co-registration of volumes, as 
implemented by MCFLIRT. Brain extraction was carried out for motion corrected BOLD 
volumes as implemented in BET. This procedure was verified with visual inspection of the 
extraction result for each data set acquired.  
 
Data denoising was performed using an independent component analysis (ICA) approach 
which was used to decompose FMRI data into different spatial and temporal components 
using FSL's MELODIC (Multivariate Exploratory Linear Optimised Decomposition into 
Independent Components34). The noise components were manually identified based on 
spatial location of signal, time course and signal frequency.35 The FSL tool FIX36,37 was 
then used as follows: 
 
1. To regress the full space of the motion confounds obtained from MCFLIRT from 
both the data and from all the ICA component time-series; 
2. To estimate the contribution of both “signal” and “noise” components as a 
means of identifying the noise specific variance; 
3. To remove the unique contribution of the components identified above as 
"noise" from the data. 
 
Additional data denoising in 13 subjects was also performed using a combination of 
physiological noise modelling integrated in FEAT (RETROICOR38,39) and ICA (described in 
40) to assess the impact of measured changes in respiratory and heart rate on ALFF 
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between sessions. We were unable to perform this correction on all datasets as five 
subjects had intermittent short (5-10 seconds) interruptions in continuous physiological 
traces during scanning which rendered analysis with RETROICOR impossible, so these 
five subject were excluded from this supplementary analysis. Results and figures from this 
analysis are presented in the Supplementary Material. 
	
We again registered the fMRI volumes to the VBM study-specific template space. The 
resulting images were smoothed with 6mm full width at half maximum (FWHM) Gaussian 
kernel. 
 
Calculation of ALFF was then performed with customised MATLAB (Mathworks Inc.) 
scripts using the Chronux Toolbox (www.chronux.org). The power of the low frequency 
fluctuations in the frequency range 0.01-0.1Hz was measured using a multi-taper spectral 
estimation41 using discrete prolate spheroidal (Slepian) sequences with five tapers, and 
fast Fourier transform algorithm for the resting-state time series for each voxel. The power 
between the 0.01-0.1Hz band was divided by the total power of the resolved frequencies 
from 0Hz to the Nyquist frequency to calculate normalised spectral power for that low 
frequency band. This was performed to look specifically at changes within this low power 
band. We used the same probabilistic mask of the thalamus to obtain average values for 
ALFF in the thalamus region. 
 
Statistical Analysis  
The contrasts of interest between conditions were: 
 
1. Effect of hypoxia on brain: Normoxia/Placebo v Hypoxia/Placebo  
2. Effect of nimodipine in normoxia: Normoxia/Placebo v Normoxia/Nimodipine  
3. Effect of nimodipine in hypoxia: Hypoxia/Placebo v Hypoxia/Nimodipine 
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Statistical differences between these conditions were assessed using permutation tests,42 
with the FSL tool randomise for the voxelwise analyses, using 5,000 permutations, and 
with the tool PALM (Permutation Analysis of Linear Models 
(https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/PALM) for the region-based analyses, using 10,000 
permutations followed by the approximation of the tail of the permutation distribution using 
a generalized Pareto distribution.43 Each p-value was adjusted for six comparisons, these 
being the three differences in the positive and negative directions. Significance for all tests 
was established at the level alpha<0.05. Finally, a repeated measures ANOVA was 
applied to the region-based data to investigate the presence of an interaction between 
drug conditions and oxygenation conditions to investigate whether nimodipine significantly 
modulates the response to hypoxia. 
 
For the voxelwise analyses in each modality, to account for the repeated measures, the 
differences were calculated between each contrast (e.g. normoxia/placebo v 
hypoxia/placebo) and then entered into a one sample t-test, assessed with sign flippings. 
Voxelwise analyses used Threshold-Free Cluster Enhancement (TFCE)44, with familywise 
error rate corrected across space. Results were considered significant at the level 
alpha<0.05. 
 
The Pearson correlation coefficient was used to investigate correlations between blood 
levels of the drug nimodipine and MRI changes seen between the Hypoxia/Placebo and 
Hypoxia/Nimodipine conditions with results considered significant at p < 0.05. 
 
RESULTS 
Complete laboratory and MRI datasets were obtained in 18 out of the 20 subjects. Two 
subjects withdrew from the study due to scheduling issues preventing completion of all 
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sessions. During pre-processing and prior to unblinding, significant motion artifact was 
discovered in one VEPCASL dataset throughout all sessions. This subject was therefore 
excluded leaving only 17 subjects for the VEPCASL group analysis. 
 
Physiological data  
Figure 2-A shows changes in mean PETO2 and Figure 2-B shows changes in end tidal 
carbon dioxide (PETCO2) levels throughout the laboratory and MRI sessions for all 
participants. The differences in PETCO2, PETO2, SpO2, heart rate and non-invasive blood 
pressure between each condition are summarized in Table 1 along with significance 
values. 
 
Compared with normoxia, as expected, the hypoxia condition significantly reduced the 
PETO2 in both the placebo and nimodipine conditions. There was a drop in PETCO2 values 
for both the placebo and nimodipine conditions with hypoxia as the laboratory and MRI 
sessions progressed.  
 
Nimodipine had no significant effect on either PETO2 or PETCO2 compared to placebo in 
either the normoxia or hypoxia conditions. Hypoxia resulted in a significant drop in SpO2 
and increase in heart rate in both placebo and nimodipine conditions. There was no 
significant difference in mean arterial pressure between normoxia and hypoxia and with 
nimodipine.  
 
Nimodipine levels 
Serum nimodipine levels for each experimental condition are presented in the Table 1. 
Importantly, there was no significant difference in nimodipine levels between the normoxia 
and hypoxia sessions (18.90 ± 20.33 ng/ml v 24.07 ± 24.62 ng/ml, p=0.73). 
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MRI Results 
Figure 3 shows the MRI results for the thalamus from the study for the DWI (Figure 3A), 
structural (Figure 3B) and perfusion-weighted images (Figure 3C). Figure 4 shows data 
from the voxelwise whole-brain comparisons for the DWI data. Figure 5 shows the results 
of the ALFF analysis. Figure 6 shows the correlations between nimodipine levels and 
change in MRI data for Hypoxia/Placebo and Hypoxia/Nimodipine conditions.  
 
Tables S2 and S3 in the supplementary material show the common local peaks of the 
significant clusters for Figure 5. 
 
Effect of acute hypoxia  
Diffusion-weighted imaging 
There was a significant decrease in ADC values in the thalamus for the hypoxia condition 
compared to the normoxia condition (1061 ± 40 v 1011 ± 75 x 10−6mm2/s, 
p=0.0002)(Figure 3A). Whole brain voxelwise analysis confirmed regional variation in grey 
matter ADC associated with the hypoxia condition, with especially noticeable decreases in 
ADC seen in the subcortical structures (thalamus, basal ganglia, hippocampus) as well as 
the cerebellum (crus I and II regions – Figure 4A). 
 
T1-weighted imaging  
Figure 3B shows that hypoxia resulted in a significant apparent increase in grey matter 
volume in the thalamus ROI when compared to normoxia (0.3924 ± 0.028 v 0.370 ± 0.037 
a.u., p=0.0027). Looking voxelwise over the whole brain though, there was no significant 
difference in grey matter volume. 
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Perfusion-weighted imaging  
Figure 3C shows the results from the ASL perfusion-weighted imaging data for each 
experimental condition. There was an increase in CBF in the thalamus ROI for the hypoxia 
condition compared to normoxia (59.15 ± 10.00 v 50.34 ± 6.68 ml/100g/min, p=0.0191). 
However, looking at the whole brain grey matter voxelwise analysis, there were no areas 
of significant difference in grey matter CBF between the normoxia and hypoxia conditions. 
 
Table 1 also presents the results for the phase contrast imaging for each experimental 
condition. Flow through both carotid arteries was significantly higher in the normoxia 
condition when compared to hypoxia. This was not the case for the vertebral arteries, 
where there was no significant difference in flow values. 
 
Amplitude of low frequency fluctuations 
There was a large increase in normalised ALFF in the thalamus (35.24 ± 2.43 v 41.20 ± 
1.85, p=<0.0001) with hypoxia compared to normoxia (Figure 5). Results for grey matter 
are provided for comparison along with full power spectra for both the thalamus ROI and 
whole brain grey matter. These differences remained significant when the additional data 
physiological denoising was conducted as described in the materials and methods section 
(See Supplementary Data). 
 
Effect of nimodipine under conditions of normoxia  
Diffusion-Weighted Imaging  
There was no significant difference between nimodipine and placebo in the thalamus 
(1061 ± 40 v 1050 ± 55 x 10-6mm2/s, p=0.1363). There was also no significant regional or 
global effect on whole brain grey matter ADC values using voxelwise analysis. 
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T1-weighted imaging  
Like the DWI data, compared with placebo, there was no significant difference in volume in 
the nimodipine condition for the thalamus (0.370 ± 0.037 v 0.3781 ± 0.035 a.u., p=0.2370) 
and no significant difference seen over whole brain grey matter using voxelwise analysis. 
 
Perfusion-weighed imaging  
There was a significantly increased thalamic CBF in the nimodipine condition compared 
with placebo (59.49 ± 11.70 ml/100g/min v 52.26 ± 6.91 ml/100g/min, p=0.037). However, 
there was no significant difference seen over whole brain grey matter using voxelwise 
analysis. Looking at the phase contrast results, velocities through carotid and vertebral 
arteries were not significantly different between the nimodipine and placebo conditions. 
 
Amplitude of low frequency fluctuations  
There was a significant reduction in normalised ALFF in the thalamus between nimodipine 
and placebo in the normoxia condition (41.20 ± 1.85 v 40.24 ± 1.88, p=0.028). Again, full 
power spectra and values for grey matter are provided for comparison in Figure 5. 
 
Effect of nimodipine under conditions of hypoxia  
Diffusion-Weighted Imaging 
In the hypoxia condition, there was a significant increase in ADC values with nimodipine 
towards baseline in the thalamus compared to placebo (1059 ± 49 v 1048 ± 34 x 10-
6mm2/s, p=0.0171). There was also a significant interaction effect between nimodipine and 
hypoxia (p=0.0002). Furthermore, there was also a significant positive correlation between 
the change in ADC values in the thalamus between hypoxia/placebo and hypoxia/drug 
conditions and serum nimodipine levels (r=0.60 p=0.0083) with higher nimodipine levels in 
subjects associated with greater change in ADC values (Figure 6). 
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Figure 4B shows the voxelwise changes between the hypoxia/placebo and 
hypoxia/nimodipine conditions. Again, there was a significant increase in ADC across 
multiple subcortical regions including the thalamus, basal ganglia (putamen and caudate), 
hippocampus and cerebellum with the administration of nimodipine. 
 
Finally, voxelwise comparison was performed between normoxia/placebo and 
hypoxia/nimodipine which showed no significant differences over whole brain grey matter 
confirming the reversal of the effect of acute hypoxia.  
 
T1-weighted imaging 
Nimodipine had no significant effect on the volume of the thalamus (0.382 ± 0.050 v 0.392 
± 0.028 a.u., p=0.5291) in hypoxia versus placebo. There was no significant interaction 
effect either between drug condition and oxygenation condition (p=0.1480). Voxelwise 
analysis showed no significant effect on whole brain grey matter volumes. 
 
Finally, there was no significant correlation between the change in the thalamus volume 
between hypoxia/placebo and hypoxia/drug conditions and serum nimodipine levels (r=-
0.04, p=0.87). 
 
Perfusion-weighted ASL imaging  
We did not observe any significant difference in the thalamus CBF under conditions of 
hypoxia for nimodipine versus placebo (60.29 ± 12.00 v 58.48 ± 7.86 ml/100g/min, 
p=0.9158) or any voxelwise differences in grey matter CBF. There was also no significant 
interaction effect (p=0.4042). There was also no significant correlation between the 
change in the thalamus CBF between hypoxia/placebo and hypoxia/drug conditions and 
serum nimodipine levels (r=-0.188 p=0.4710).  
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Looking at the phase contrast results, velocities through both carotid and vertebral arteries 
were not significantly different between the nimodipine and placebo conditions under 
conditions of hypoxia. 
 
Amplitude of low frequency fluctuations  
In the thalamus, there was a significant increase in ALFF with nimodipine when compared 
to placebo (37.87 ± 1.66 v 35.24 ± 2.43, p=0.0003)(Figure 5). Furthermore, there was a 
significant interaction effect between drug and oxygenation conditions (p=0.0002). Like the 
DWI results, the degree of increase in thalamic ALFF with nimodipine in hypoxia showed a 
significant positive correlation with nimodipine levels (r=0.54, p=0.02). 
 
DISCUSSION 
The aim of this study was to test the hypothesis that calcium channel activity mediates the 
cerebral response to inspiratory hypoxia in vivo in humans. Through this, we aimed to 
clarify the role of calcium in the pathophysiology of acute brain injury in clinical practice. 
Several notable findings have arisen from this study. Firstly, acute hypoxia causes a clear 
reduction in ADC and ALFF values in the thalamus. These changes are accompanied by 
an apparent increase in thalamic volume, together with an increase in thalamic CBF. 
Calcium channel blockade with nimodipine attenuated the effects of cerebral hypoxia on 
ADC and ALFF values seen in the thalamus and other cortical/sub-cortical areas, returning 
values back towards baseline levels seen in normoxia. Finally, changes in ADC and ALFF 
with nimodipine showed a significant correlation with nimodipine levels in hypoxia. 
 
Cerebral effects of acute hypoxia  
Previous studies using MRI to investigate the effect of acute hypoxia on the brain have 
reported contradictory results showing either increased17,19 or reduced18,45,46 ADC values. 
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This may be due to differences in study/MRI protocols, duration of hypoxic stimulus and 
barometric pressures. In our study, the duration of hypoxia was chosen at four hours in 
order to compensate for initial changes in cerebral blood flow and ventilation that occur in 
the first 30 minutes post-hypoxic stimulus47 and to allow potential MRI biomarkers of 
pathophysiological changes associated with hypoxia to develop. Our results demonstrate 
that the thalamus is sensitive to acute inspiratory hypoxia with significantly decreased ADC 
values. These results were replicated in a secondary voxelwise whole brain analysis. This 
further highlighted decreased ADC in other subcortical structures such as the caudate, 
putamen, hippocampus and cerebellum – areas also known to be susceptible to hypoxic-
ischaemic damage. Reduced ADC values are generally interpreted to be due to cytotoxic 
oedema associated with intracellular swelling, and are associated with changes in cellular 
energy status responsible for reduced Na+/K+ ATPase pump and altered ionic 
homeostasis.17,19 
 
Analysis of the T1-weighted data shows that thalamic volume was apparently increased 
with acute hypoxia. Other studies have reported similar effects following exposure to acute 
hypoxia with increased total brain and grey matter volumes associated with reduced whole 
brain ADC.18,45 This increase is likely to result from cellular swelling due to cerebral 
oedema associated with inspiratory hypoxia. MRI evidence of cerebral oedema has also 
been noted as early as the first hour of hypoxic exposure, associated with significant shifts 
in intracranial CSF volumes.48 
 
 The results from the VEPCASL analysis suggest this increase may be due to the increase 
in CBF seen with acute hypoxia on CBF in the thalamus. Voxelwise changes in CBF were 
not seen over the whole-brain which is in concordance with other studies which have 
reported no difference in whole brain grey matter CBF in acute poikilopcapnic hypoxia.45. It 
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may also reflect the cerebral vasoconstriction that occurs because of the increased 
ventilatory response to hypoxia as well as issues with signal-to-noise ratio seen with ASL 
studies. 
 
Effects of calcium channel blockade on cerebral physiology during normoxia. 
In normoxia, nimodipine had no significant effect on ADC nor grey matter volume in the 
thalamus. However, there was a significant 14% increase in thalamic CBF and a reduction 
in ALFF. Nimodipine is characterized by a highly selective action on cerebral blood vessels 
and a high affinity to receptors in the cerebral cortex - hence the interest in its use clinically 
following acute brain injury. However, the literature investigating the effect of nimodipine 
on CBF is inconsistent. Early studies in animals under conditions of ischaemia 
demonstrated no effect on cerebral metabolism but increases in CBF due to a direct 
vasodilatory effect across all brain regions, particularly following disruption of the blood-
brain barrier.4,49-51 However, nimodipine had no significant effect on normal CBF or 
metabolism in animals.52 Early studies into nimodipine in both healthy volunteers and 
patients suffering from stroke suggested a small overall increase in CBF after nimodipine 
treatment, with a redistribution of blood to hypoperfused regions in patients.53,54 However, 
subsequent studies have shown no effect of nimodipine in healthy volunteers in 
concordance with the results of our study. 55 This may be as a result of differences in drug 
dose and timing as well as differences in CBF measurement techniques.  
 
The effect of nimodipine under conditions of cerebral hypoxia  
Results from this study demonstrate that nimodipine reverses decreases in both ADC and 
ALFF seen in the thalamus with acute hypoxia without an apparent effect on CBF The 
whole brain analysis also showed similar increases in ADC across the GM including 
subcortical structures such as the putamen, caudate, hippocampus and cerebellum. There 
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was also a significant positive correlation between the change in ADC values between 
Hypoxia/Placebo and Hypoxia/Nimodipine conditions and serum nimodipine levels in the 
thalamus. Voltage-gated calcium channels are essential for calcium signaling in excitable 
cells and play a key role in the final common pathway of acute cerebral ischaemia. 
Furthermore, L-type channels are known to display a particularly high sensitivity to 
hypoxia.56 In experimental models of focal and global ischemia, L-type calcium channel 
antagonism with nimodipine has been shown to have a neuroprotective effect, attenuating 
cognitive dysfunction and increasing the hypoxic tolerance of brain tissue.57,58 Nimodipine 
has also consistently been shown to reduce the incidence of secondary cerebral 
ischaemia and improve clinical outcomes after aneurysmal subarachnoid haemorrhage59-61 
– without any effect on cerebral vasodilatation.  
 
Our results suggest that calcium channel blockade with nimodipine acts to reduce 
cytotoxic cerebral oedema following acute cerebral hypoxia without increased CBF. Other 
studies have suggested that nimodipine may have an effect on cerebral metabolism62 
which may underlie this effect on ADC and explain the clinical benefit seen in SAH, a 
condition characterized by high levels of cytotoxic cerebral oedema. Finally, there did not 
appear to be a difference in PETCO2 with nimodipine, suggesting that changes in CBF are 
unlikely to be due to differences in ventilatory control. Other studies have demonstrated 
that nimodipine does not seem to exert a significant impact on the effect of 
hyperventilation in reducing regional CBF63 and interferes with the CBF response to 
alterations in arterial CO2.64 This may partially explain why there was no significant 
increase in CBF with nimodipine under conditions of hypoxia. 
 
The variation in nimodipine levels despite consistent dosing between subjects suggests 
that the pharmacodynamics of the oral administration route may be an important factor in 
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the use of nimodipine clinically in patients. There was also a strong correlation between 
serum nimodipine levels and changes in ADC and ALFF seen with nimodipine in hypoxia. 
This highlights that monitoring of drug levels may be important if consistent clinical 
outcome benefits are to be achieved e.g. following subarachnoid haemorrhage. 
 
Amplitude of low frequency oscillations  
To date, no other studies have considered the exact role of the ALFF in cerebral hypoxia. 
Clinical studies have suggested that changes in ALFF in disease states may be a marker 
of brain damage. Altered ALFF in frontal brain regions is seen in patients recovering from 
traumatic brain injury20, as well as in the cerebellum in patients with migraine and 
depression.65,66 Increased ALFF in the thalamus is also positively correlated with 
microstructural damage seen on MRI in multiple sclerosis.67 Our results show that acute 
inspiratory hypoxia results in a significant drop in thalamic ALFF in the BOLD signal 
replicating changes seen in disease states. Calcium channel blockade with nimodipine in 
normoxia also leads to a significant decrease in ALFF in the thalamus – potentially due to 
the role of calcium oscillations in resting brain neuronal activity. However, in the presence 
of hypoxia, the administration of nimodipine significantly increases ALFF normalizing 
levels to those seen in normoxia. Regional heterogeneity in the BOLD response to hypoxia 
has previously been reported in both animal studies68,69 and studies in humans.70 The 
underlying mechanisms that could lead to this are poorly understood and include different 
changes in total deoxyhaemoglobin for a fixed change in arterial oxygen saturation due to 
different blood volumes and/or different oxygen extraction fractions and flow-induced 
variation in saturation and signal intensity.69 It may be that subcortical structures such as 
the thalamus have a different oxygen extraction fraction at rest than other areas of the 
brain and are therefore more sensitive to changes in arterial oxygen content. Though the 
absence of significant correlation between CBF and change in ALFF with nimodipine in 
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hypoxia suggests that this difference may be related to a mechanism of action of calcium 
channel blockade on neurons (potentially via an effect on low frequency oscillations in 
calcium levels) rather than a direct vascular effect. 
 
CONCLUSION 
In summary, we have provided evidence for a preferential effect of calcium channel 
blockade with nimodipine under conditions of acute cerebral hypoxia in reversing changes 
in ADC and ALFF in the thalamus. These changes to ADC and ALFF may underlie the 
benefit seen clinically in conditions like SAH where significant global cytotoxic cerebral 
oedema is seen with early brain injury. Further research is needed into the importance of 
changes in ALFF with hypoxia and whether this represents a biomarker of cerebral tissue 
hypoxia in acute acquired brain injury.   
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FIGURE LEGENDS 
Figure 1: A: Study protocol. B: Schematic diagram of the breathing apparatus used to 
maintain hypoxic conditions in both the laboratory and MRI sessions 
 
Figure 2: A: PETO2 values from the laboratory and MRI sessions. B: PETCO2 values from 
the laboratory and MRI sessions 
 
Figure 3: Graphs showing changes in the thalamus for A: apparent diffusion coefficient 
(ADC), B: volume and C: cerebral blood flow in each of the four experimental conditions 
 
Figure 4: A: Regional areas of decreased grey matter apparent diffusion coefficient (ADC) 
in the hypoxia/placebo condition compared to normoxia/placebo. (In yellow, p<0.05 FWE-
corrected for multiple comparisons, overlaid onto an MNI152 standard template).  B: 
Regional areas of increased grey matter apparent diffusion coefficient (ADC) in the 
hypoxia/nimodipine condition compared to hypoxia/placebo. (In yellow, p<0.05, overlaid 
onto an MNI152 standard template 
 
Figure 5: A: Thalamus and B: whole brain grey matter change in ALFF and frequency 
spectrograms for placebo and nimodipine conditions in normoxia and hypoxia (graphs 
show mean (solid line) with 95% CI (shaded areas)) 
 
Figure 6: Correlations for the VBM, DWI, CBF and ALFF analysis between nimodipine 
levels and effect of nimodipine in hypoxia (Hypoxia/Drug - Hypoxia/Placebo) 
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TABLES 
Table 1: Physiological data, nimodipine levels and phase contrast MRI results for each 
experimental condition.  
 
Normoxia 
Placebo 
Normoxia 
Nimodipine 
Hypoxia 
Placebo 
Hypoxia 
Nimodipine 
SpO2 (%) 98 ± 1*** 98 ± 1 85 ± 6*** 84 ± 7 
HR (bpm) 67 ± 2*** 68 ± 2 77 ± 3*** 79 ± 3 
SBP (mmHg) 115 ± 15 114 ± 12 119 ± 12 116 ± 16 
DBP (mmHg) 64 ± 6 62 ± 7 64 ± 6 64 ± 6 
MAP (mmHg) 80 ± 7 79 ± 9 82 ± 9 82 ± 8 
PETO2 (KPa) 14.17 ± 0.12*** 14.36 ± 0.19 7.38 ± 1.18*** 7.48 ± 1.21 
PETCO2 (KPa) 5.35 ± 0.04*** 5.32 ± 0.08 4.80 ± 0.37*** 4.83 ± 0.29 
     
Nimodipine levels 
(ng/ml) 
0 18.90 ± 20.33 0 24.07 ± 24.62 
     
Phase Contrast 
Velocities 
    
Left carotid (cm/s) 30.93***± 5.32 28.66 ± 5.92 28.37*** ± 4.97 27.07 ± 4.46 
Right carotid (cm/s) 31.22* ± 4.19 31.05 ± 5.67 30.38* ± 5.21 28.24 ± 5.03 
Left vertebral(cm/s) 14.50 ± 3.55 14.28 ± 2.39 13.87 ± 3.43 13.22 ± 3.10 
Right vertebral (cm/s) 11.95 ± 3.59 11.92 ± 4.43 11.96 ± 4.75 11.51 ± 2.99 
 
 
Results are presented as mean ± standard deviation (SpO2=oxygen saturations, 
HR=heart rate, SBP=systolic blood pressure, DBP=diastolic blood pressure, MAP=mean 
arterial pressure, ETO2=end tidal oxygen, ETCO2=end tidal carbon dioxide).  
 
SpO2 - Normoxia/Placebo v Hypoxia Placebo: p=< 0.001 
HR - Normoxia/Placebo v Hypoxia Placebo: p=< 0.001 
ETO2 - Normoxia/Placebo v Hypoxia Placebo: p=<0.001 
ETCO2 - Normoxia/Placebo v Hypoxia Placebo:  p=<0.001 
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Left carotid: Normoxia/Placebo v Hypoxia Placebo: p=0.001 
Right carotid: Normoxia/Placebo v Hypoxia Placebo: p=0.0328 
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Table S1: Common local peaks of the significant clusters (P < 0.05 FWE-corrected) showing 
reduced ADC in hypoxia in contrast to normoxia in the placebo condition. Local maximum t values 
correspond to Figure 5A.  
 
Cortical Region Side MNI Coordinates Local maximum t 
GM Visual Cortex V5 Lt -52 -66 -6 6.6 
GM Visual Cortex V2 Lt -4 -70 30 3.98 
GM Visual Cortex V1 Rt 18 -68 8 4.94 
Auditory cortex Rt 48 -16 8 4.78 
Parahippocampal gyrus Rt 20 -10 -30 5.66 
Entorhinal cortex Rt 22 -6 -36 5.47 
Superior temporal gyrus Rt 50 -22 0 5.93 
Middle temporal gyrus Rt 56 -20 -18 6.3 
Inferior temporal gyrus Rt 54 -52 -20 5.22 
Temporal fusiform cortex Lt -32 -24 -24 4.26 
Frontal operculum cortex Rt -42 28 2 5.63 
Central operculum cortex Rt 56 -8 14 4.0 
Frontal pole Lt -46 48 0 4.42 
Frontal medial cortex Lt -12 38 -10 3.37 
Frontal orbital cortex Lt -48 28 -14 3.03 
Inferior frontal gyrus Lt -54 14 16 5.18 
Precentral gyrus Lt -12 -28 44 5.12 
Postcentral gyrus Lt -62 -16 24 3.91 
Paracingulate gyrus Rt 8 48 -2 4.85 
Cingulate gyrus Rt 4 -48 20 4.44 
Superior parietal lobule Lt -2 -38 58 3.52 
Inferior parietal lobule Rt 50 -34 30 4.95 
Inferior parietal lobule (angular 
gyrus) 
Rt 52 -52 18 4.3 
Insular cortex Lt -42 4 -4 4.63 
Precuneus cortex Rt 22 -56 20 4.01 
Thalamus Rt 12 -18 8 5.0 
 Lt -16 -20 12 4.25 
Putamen Rt 32 -16 -2 4.74 
Putamen Lt -28 -18 6 3.25 
Caudate Rt 10 6 4 3.13 
Hippocampus  Lt -22 -38 0 4.76 
Amygdala Lt -26 -6 -20 3.4 
      
Cerebellum      
Cerebellum (VIIb) Lt -22 -72 -46 6.15 
Cerebellum (VIIb) Rt 16 -74 -44 3.29 
Cerebellum (Vermis VIIa) Rt 6 -68 -38 6.4 
Cerebellum (VI) Lt -12 -74 -20 6.4 
Cerebellum (VI) Rt 14 -64 -22 3.9 
Cerebellum (Crus II) Lt -36 -62 -42 5.16 
Cerebellum (Crus II) Rt 48 -64 -48 4.12 
Cerebellum (Crus I) Rt 40 -66 -28 4.95 
Cerebellum (Crus I) Lt -38 -56 -28 4.83 
Cerebellum (I-IV) Rt 8 -50 -20 4.39 
Cerebellum (I-IV) Lt -4 -54 -18 3.94 
  
 
Table S2: Common local peaks of the significant clusters (P < 0.05 FWE-corrected) showing 
increased ADC with nimodipine in hypoxia in contrast to placebo. Local maximum t values 
correspond to Fig. 5B. GM = Grey matter 
 
Cortical Region Side MNI Coordinates Local maximum t 
GM Visual Cortex V2 Lt -18 -54 -6 3.05 
GM Visual Cortex V1 (BA 17) Lt -2 -64 4 3.18 
Superior parietal lobule Lt -26 -66 48 4.04 
Supramarginal gyrus Lt -56 -48 24 4.07 
Inferior parietal lobule Rt 58 -36 52 6.3 
Lateral occipital cortex Lt -42 -74 -6 5.33 
Frontal pole Rt 24 56 -6 4.02 
Frontal pole Lt -38 50 -2 4.08 
Premotor cortex (BA 6) Rt 8 2 48 3.36 
Entorhinal cortex Lt -30 -8 -42 5.76 
Precentral gyrus (BA 44) Lt -52 6 8 3.45 
Postcentral gyrus Lt -68 -14 14 6.11 
Postcentral gyrus Rt 66 -8 32 3.06 
Superior frontal gyrus (BA 1) Lt -20 36 36 4.21 
Middle frontal gyrus (BA44) Rt 26 32 38 4.77 
Superior temporal gyrus Lt -56 -38 8 3.34 
Middle temporal gyrus Lt -58 -46 -4 4.03 
Middle temporal gyrus Lt -44 -28 -26 3.21 
Temporal pole Lt -34 6 -38 4.22 
Cingulate gyrus Rt 10 -50 24 3.95 
Paracingulate gyrus Rt 10 46 -4 3.8 
Hippocampus Rt 22 -8 -24 4.19 
Parahippocampal gyrus Lt -24 -40 -16 3.31 
Parahippocampal gyrus Rt 34 -34 -14 3.36 
Thalamus Rt 8 -16 0 3.59 
Hippocampus  Lt -18 -38 2 3.94 
Putamen Lt -30 0 -6 3.47 
Putamen Rt 24 8 4 4.15 
Subcallosal cortex Rt 12 16 -14 3.08 
Insular cortex Lt -42 -12 2 3.04 
      
Cerebellum      
Cerebellum (Crus II) Lt -18 -78 -48 4.08 
Cerebellum (VI) Lt -22 -72 -22 3.68 
Cerebellum (VI) Rt 18 -62 -24 4.21 
Cerebellum (V) Rt 16 -50 -24 4.11 
Cerebellum (I-IV) Lt -2 -52 -14 3.28 
 
 
 
 
 
 
 
 
  
 
Figure S3: ALFF results in the thalamus for each experimental condition following supplementary 
data denoising with FIX and RETROICOR 
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Figure S4: Graphs of spectral power for each experimental condition for the thalamus ROI 
following denoising with both ICA and RETROICOR 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3: Graphs of spectral power for each experimental condition for whole brain grey matter 
following denoising with both ICA and RETROICOR 
Figure S3: Graphs of spectral power for each experimental condition for the thalamus ROI with no 
data denoising 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure S5: Graphs of spectral power for each experimental condition for whole brain grey matter 
following denoising with both ICA and RETROICOR 
 
 
 
 
 
 
 
Figure S3: Graphs of spectral power for each experimental condition for the thalamus ROI with no 
data denoising 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure S6: Graphs of spectral power for each experimental condition for the thalamus ROI with no 
data denoising 
 
 
